SequelSEC

GRI Bio, Inc. GRI

Pharmaceutical Preparations · CIK 0001824293 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$0
Fiscal year ended 2022-03-31
Operating income
-$2.63M
Fiscal year ended 2022-03-31
Free cash flow
Unavailable
Fiscal year ended 2022-03-31

GRI Bio, Inc. (GRI) reported revenue of $0 and net income of -$302.00K for the fiscal year ended 2022-03-31. This page shows 9 annual periods of income statement, balance sheet and cash flow figures normalized from GRI Bio, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

GRI Bio, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-31
Revenue$0$0$0$0$0$0$0$0$100.00K
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$2.63M-$3.09M-$1.25M-$2.31M-$2.60M-$1.46M-$1.03M-$1.14M-$1.16M
Net income-$302.00K-$3.10M-$1.26M-$2.31M-$2.64M-$1.47M-$1.04M-$1.15M-$1.16M
Research & development$1.27M$2.00M$215.00K$1.20M$1.77M$1.28M$733.00K$808.00K$883.00K
Weighted-average diluted sharesUnavailableUnavailableshares 6.81Mshares 6.81Mshares 5.71MUnavailableshares 4.51Mshares 4.51MUnavailable
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expenseUnavailableUnavailableUnavailableUnavailable$0UnavailableUnavailableUnavailable$0
Diluted EPS$-11.62Unavailable$-0.18$-0.34$-0.46Unavailable$-0.23$-0.25Unavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailable$830.00KUnavailableUnavailableUnavailable$375.00K
General & administrative$1.36M$1.10M$1.04M$1.11M$830.00K$180.00K$300.00K$327.00KUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

GRI Bio, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-31
Cash & equivalents$2.54M$3.70M$5.88M$10.46M$12.98M$109.00KUnavailableUnavailableUnavailable
Total assets$5.94M$8.34M$10.14M$11.65M$14.60M$955.00KUnavailableUnavailableUnavailable
Current assets$5.76M$8.13M$9.92M$11.40M$14.34M$674.00KUnavailableUnavailableUnavailable
Total liabilities$2.58M$2.52M$1.41M$1.79M$2.57M$2.41MUnavailableUnavailableUnavailable
Current liabilities$2.54M$2.44M$1.31M$1.67M$2.43M$2.22MUnavailableUnavailableUnavailable
Total equity incl. NCI-$5.15M-$4.85M$8.73M$9.85M$12.03M-$1.45M-$24.00K$969.00K$2.09M
Temporary (mezzanine) equity$124.00K$124.00KUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$1.23M$918.00K$488.00K$886.00K$1.35M$1.23MUnavailableUnavailableUnavailable

Cash flow

GRI Bio, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-31
Operating cash flow-$2.29M-$1.58M-$1.29M-$2.49M-$2.95M-$808.00K-$1.06M-$1.07M-$766.00K
Capital expendituresUnavailable$0$0UnavailableUnavailable$0$0$0$2.00K
Investing cash flow$1.15M-$576.00K-$3.27M$0$0$0$0$0-$2.00K
Financing cash flow-$23.00K-$23.00K-$21.00K-$28.00K$15.82M-$7.00K-$11.00K$43.00K-$29.00K
Net change in cash-$1.16M-$2.18M-$4.58M-$2.52M$12.87M-$815.00K-$1.08M-$1.02M-$797.00K
Stock-based compensation$181.00K$186.00K$134.00K$138.00K$168.00K$39.00K$52.00K$28.00K$35.00K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

GRI Bio, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-31
Free cash flowUnavailableUnavailableUnavailableUnavailableUnavailable-$808.00K-$1.06M-$1.07M-$768.00K
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable-1158.0%
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable-768.0%
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable35.0%
Current ratio2.27x3.32x7.55x6.82x5.91x0.30xUnavailableUnavailableUnavailable
Revenue YoY growthUnavailableUnavailableUnavailableUnavailable-100.0%UnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable883.0%
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable2.0%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open GRI in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-13View SEC filing
10-K · Filed 2026-01-30View SEC filing
10-Q · Filed 2025-11-14View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-15View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Reconciliation checks needing review

2 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

balance equationreview2022-03-31

Difference 8386000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.

balance equationreview2021-12-31

Difference 10542000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.